Home » AFFYMAX ANNOUNCES RESULTS OF HEMATIDE TRIAL
AFFYMAX ANNOUNCES RESULTS OF HEMATIDE TRIAL
Affymax has announced results from a Phase II clinical trial of Hematide in
patients with anemia due to chronic kidney disease (CKD). Hematide is a novel
peptide-based drug candidate designed to stimulate the production of red blood
cells.
The trial is a randomized, double-blind, placebo-controlled, dose-escalation
study evaluating a single intravenous injection of Hematide administered to
patients with CKD. The study found that Hematide was well-tolerated and demonstrated
potent and sustained erythropoietic activity of the same magnitude as that observed
in healthy volunteers.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May